Myelodysplastic Syndromes Resources

Access clinical resources, education and the latest research to help guide decision-making when considering transplant as a treatment for patients with Myelodysplastic Syndromes (MDS).

Mobile app 

• Transplant Guidelines Mobile App includes recommended timing for transplant consultation for MDS and 15 other diseases, outcomes data, post-transplant care recommendations and transplant news 

Online clinical resources 

• Trends in HCT for MDS clinical fact sheet 
• MDS outcomes data slides 
• MDS Edition: Advances in Transplantation newsletter (PDF) 
• Recommended Timing for Transplant Consultation 
• Post transplant care guidelines 

 Online education programs 

• Options for High-Risk AML and MDS 
• Advances in AML/MDS: The Role of Multi-center Clinical Trials 

Current MDS research

• HCT for MDS Medicare Study: CIBMTR (Center for International Blood and Marrow Transplant Research)
• Acute Leukemia Working Committee studies: CIBMTR (Center for International Blood and Marrow Transplant Research) 
• Multi-institutional phase II and III clinical trial protocols including MDS: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 

Recently published research 

Patient age

• Cutler, C. Transplantation for MDS in the elderly: more evidence, or more bias? Biol Blood Marrow Transplant. 2012; 18(9): 1320-1321. Access article >  
• Kröger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood. 2012; 119(24): 5632-5639. Access article > 
• Platzbecker U, Schetelig J, Finke J, et al. Allogeneic hematopoietic cell transplantation in patients aged 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant. 2012; 18(9): 1415-1421. Access article > 
• Strahm B, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOGMDS 98 study. Leukemia. 2011; 25(3): 455-462. Access article > 

Conditioning regimens 

• Gerds AT, Gooley TA, Estey EH, et al. Pre-transplantation therapy with azacitidine vs induction chemotherapy and post-transplantation outcome in patients with MDS. Biol Blood Marrow Transplant. 2012; 18(8): 1211-1218. Access article > 
• Kim D-Y, Lee J-H, Park Y-H, et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant. 2011; 47(3): 374–379. Access article > 
• Luger SM, Ringdén O, Zhang M-J, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2011; 47(2): 203-211. Access article > 
• Steensma D. Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2012; 18(8): 1145-1147. Access article >